drugset / Trial / NCT04189094
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
Phase 2
Unknown
140 enrolled
Zhejiang Cancer Hospital
Affiliated Hospital of Guangdong Medical University · collabFirst Affiliated Hospital, Sun Yat-Sen University · collabFirst People's Hospital of Foshan · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is a prospective, multi-center, open-label, randomized, and controlled phase II clinical trial.
Timeline
- Start
- 2020-01-01
- Primary completion
- 2021-07-01
- Completion
- 2023-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | — | — |
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |